Published April 11, 2008 | Version v1
Journal article

Prognostic Impact of Array-based Genomic Profiles in Esophageal Squamous Cell Cancer

  • 1. Department of Clinical Oncology, Portuguese Institute of Oncology, 1099-023 Lisbon (Portugal)
  • 2. Department of Oncology, Lund University Hospital, 221 85 Lund (Sweden)
  • 3. Department of Surgery, University Hospital, 221 85 Lund (Sweden)
  • 4. Department of Surgery, Helsingborg Hospital, 251 87 Helsingborg (Sweden)
  • 5. Department of Pathology, Helsingborg Hospital, 251 87 Helsingborg (Sweden)
  • 6. Department of Clinical Sciences, Copenhagen University and Clinical Research Unit, Hvidovre Hospital, 2650 Hvidovre (Denmark)

Description

Esophageal squamous cell carcinoma (ESCC) is a genetically complex tumor type and a major cause of cancer related mortality. Although distinct genetic alterations have been linked to ESCC development and prognosis, the genetic alterations have not gained clinical applicability. We applied array-based comparative genomic hybridization (aCGH) to obtain a whole genome copy number profile relevant for identifying deranged pathways and clinically applicable markers. A 32 k aCGH platform was used for high resolution mapping of copy number changes in 30 stage I-IV ESCC. Potential interdependent alterations and deranged pathways were identified and copy number changes were correlated to stage, differentiation and survival. Copy number alterations affected median 19% of the genome and included recurrent gains of chromosome regions 5p, 7p, 7q, 8q, 10q, 11q, 12p, 14q, 16p, 17p, 19p, 19q, and 20q and losses of 3p, 5q, 8p, 9p and 11q. High-level amplifications were observed in 30 regions and recurrently involved 7p11 (EGFR), 11q13 (MYEOV, CCND1, FGF4, FGF3, PPFIA, FAD, TMEM16A, CTTS and SHANK2) and 11q22 (PDFG). Gain of 7p22.3 predicted nodal metastases and gains of 1p36.32 and 19p13.3 independently predicted poor survival in multivariate analysis. aCGH profiling verified genetic complexity in ESCC and herein identified imbalances of multiple central tumorigenic pathways. Distinct gains correlate with clinicopathological variables and independently predict survival, suggesting clinical applicability of genomic profiling in ESCC

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-8-98; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374796

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
8
Journal Page Range
p. 98
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46091924
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; MAPPING; METASTASES; MORTALITY; MULTIVARIATE ANALYSIS; RESOLUTION
Descriptors DEC
DISEASES; MATHEMATICS; NEOPLASMS; STATISTICS

Optional Information

Copyright
Copyright (c) 2008 Carneiro et al
Notes
PMCID: PMC2374796; PUBLISHER-ID: 1471-2407-8-98; PMID: 18405350; OAI: oai:pubmedcentral.nih.gov:2374796; licensee BioMed Central Ltd.